AI assistant
Sending…
Aptevo Therapeutics Inc. — Director's Dealing 2018
Mar 6, 2018
35422_dirs_2018-03-05_75f2584a-da0e-4a66-b069-6de358482570.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2018-03-01
Reporting Person: Stromatt Scott C (Chief Medical Officer and SVP)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-03-01 | Common Stock | M | 16269 | — | Acquired | 190845 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-03-01 | Restricted Stock Unit | $ | M | 16269 | Disposed | Common Stock (16269) | Direct |
Footnotes
F1: Each RSU converts into the Issuer's common stock on a one-for-one basis.
F2: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments on the anniversary of the grant date.
More from Aptevo Therapeutics Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Mar 27
Declaration of Voting Results & Voting Rights Announcements
2026
Feb 19
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Board/Management Information
2026
Feb 3
Capital/Financing Update
2026
Jan 30
Capital/Financing Update
2026
Jan 28
Proxy Solicitation & Information Statement
2026
Jan 26